Voyager Acquisition Corporation has announced that its shareholders have approved the business combination with VERAXA Biotech AG. This significant step paves the way for the combined entity to trade on Nasdaq under the new ticker symbol “VRXA.” The approval follows a substantial shareholder redemption rate, with nearly all Class A shares being redeemed.
Voyager Acquisition Corporation held a general meeting on March 12, 2026, where shareholders voted to approve the business combination with VERAXA Biotech AG. This approval is a critical milestone for the merger. However, the transaction saw a significant number of Class A ordinary shares redeemed by holders exercising their right to a pro rata portion of the company’s trust account funds. A total of 25,217,315 Class A shares were redeemed, representing approximately 99.67% of the outstanding Class A shares. Following these redemptions, an estimated $885,556 is expected to remain in the trust account, with 82,685 Class A shares converting into shares of the combined company, Veraxa Biotech Holding AG.
VERAXA Biotech AG is an emerging leader in the development of novel cancer therapies. The company specializes in designing next-generation antibody-based therapeutics, including bispecific antibody-drug conjugates (ADCs) and bispecific T cell engagers. Founded on scientific breakthroughs from the European Molecular Biology Laboratory, VERAXA is advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development. Christoph Antz, Ph.D., serves as the Chief Executive Officer of VERAXA.
With shareholder approval secured, the next steps involve satisfying customary closing conditions and obtaining listing approvals from Nasdaq. Upon successful completion of the business combination, the merged entity will operate as Veraxa Biotech Holding AG and is anticipated to commence trading on the Nasdaq stock exchange under the new ticker symbol “VRXA.” VERAXA’s existing management team, led by CEO Christoph Antz, is expected to continue managing the combined company.
Both Voyager and VERAXA have included standard forward-looking statements in their announcements, cautioning that actual results may differ materially from those projected due to various risks and uncertainties. These statements are based on current expectations and are subject to factors beyond the companies’ control. Investors are advised to consult the filings made with the Securities and Exchange Commission (SEC) for a more comprehensive understanding of the transaction and associated risks.